First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.

"Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."

Participants will receive single dose of 1 mg glucagon s.c. injection.

Participants will receive single dose of placebo (for double dummy injections).